Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Acute hemodynamic effects of TPN171H in pulmonary arterial hypertension: a randomized, controlled, phase 2a trial

Fig. 2The alternative text for this image may have been generated using AI.

Maximum change in PVR from baseline to 24 h. Mean maximum changes (in %) from baseline to 24 h in PVR in each group. Compared to the placebo group, the least-squares mean differences were −16.8% (95% CI, −29.1 to −4.5, p = 0.008), −15.4% (95% CI, −28.2 to −2.7, p = 0.019) and −13.3% (95% CI, −25.6 to −0.9, p = 0.036) in the TPN171H 5 mg, Tadalafil 20 mg, and Tadalafil 40 mg groups, respectively. The maximum changes in PVR of the TPN171H 2.5 and 10 mg groups did not differ significantly from the placebo group. An analysis of covariance model was used, with the maximum change in pulmonary vascular resistance as a percentage from baseline as the dependent variable, treatment as a fixed effect, and baseline pulmonary vascular resistance as a covariate. PVR pulmonary vascular resistance

Back to article page